CHICAGO, Sept. 2 /PRNewswire/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it will present at Rodman and Renshaw‘s 12th Annual Healthcare Conference held September 12-15th in New York City.
(Logo: http://photos.prnewswire.com/prnh/20080218/ALSLOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)
Advanced Life Sciences’ President and Chief Financial Officer, John Flavin, will make a corporate presentation to investors at Rodman and Renshaw‘s Global Investment Conference on Tuesday, September 14 at 3:15 PM ET. The Company’s presentation will be delivered in the Fahnestock Salon at The New York Palace Hotel, 455 Madison Avenue in New York City. The webcast can be accessed through the Investor Relations page on the Advanced Life Sciences website, www.advancedlifesciences.com. Those interested in listening to the presentation should log on a few minutes in advance in order to download any software or complete any sign-in that may be required.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company’s lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including community acquired bacterial pneumonia (CABP) and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.
Forward-Looking Statements
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management’s judgment regarding future events. The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise. Our actual results could differ materially from those discussed herein due to several factors including the success and timing of our clinical trials and our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, future revenues and capital requirements; our ability to obtain financing on terms acceptable to us; our ability to obtain and maintain intellectual property protection for our product candidates; the successful development of our sales and marketing capabilities; the success of competing drugs that become available; and the performance of third party collaborators and manufacturers. These and additional risks and uncertainties are detailed in the Company’s filings with the Securities and Exchange Commission.
SOURCE Advanced Life Sciences Holdings, Inc.
